Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M12.0Revenue (TTM) $M12.7Net Margin (%)-136.5Altman Z-Score-4.2
Enterprise Value $M6.3EPS (TTM) $-7.2Operating Margin %-87.0Piotroski F-Score3
P/E(ttm)--Beneish M-Score-2.7Pre-tax Margin (%)-136.5Higher ROA y-yY
Price/Book0.410-y EBITDA Growth Rate %-11.0Quick Ratio2.0Cash flow > EarningsY
Price/Sales0.75-y EBITDA Growth Rate %4.3Current Ratio2.6Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-33.6Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-50.2Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M3.0ROIC % (ttm)-37.0Gross Margin Increase y-yN

Gurus Latest Trades with KOOL

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
KOOLKen Fisher 2011-09-30 Sold Out -0.0001%$24 - $42.6
($34.42)
$ 4.00-88%Sold Out0
KOOLKen Fisher 2011-06-30 Buy $38.2 - $49.4
($43.87)
$ 4.00-91%New holding1,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

KOOL is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


KOOL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Harris KennethFormer Director/Officer 2015-11-10Sell4,043$12-66.67view
Harris KennethFormer Director/Officer 2015-11-03Sell526$12-66.67view
Harris KennethFormer Director/Officer 2015-10-29Sell432$12-66.67view
Plavan Matthew TFormer CEO 2015-09-02Sell864$13.6-70.59view
Rhein Denis MichaelDirector 2014-12-01Sell0$0-70.59view
ENGLE J MELVILLEChairman & CEO 2011-03-10Buy1,125$46-91.3view
ARTILES JORGEVP, Quality/Regulatory Affairs 2010-01-13Buy5$48.8-91.8view
ENGLE J MELVILLECEO 2009-09-25Buy1,250$45.6-91.23view
MCENANY PATRICK JDirector 2009-05-19Buy313$46.4-91.38view
ENGLE J MELVILLECEO 2009-05-12Buy1,250$44-90.91view

Quarterly/Annual Reports about KOOL:

News about KOOL:

Articles On GuruFocus.com
THERMOGENESIS Corp. Reports Operating Results (10-Q) Feb 11 2011 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Nov 04 2010 
THERMOGENESIS Corp. Reports Operating Results (10-Q) May 07 2010 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Feb 04 2010 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Nov 09 2009 
THERMOGENESIS Corp. (KOOL) CEO J Melville Engle buys 100,000 Shares Sep 28 2009 
THERMOGENESIS Corp. (KOOL) CEO J Melville Engle buys 100,000 Shares May 12 2009 
THERMOGENESIS Corp. Reports Operating Results (10-Q) May 07 2009 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Feb 05 2009 

More From Other Websites
Chinese stem-cell research company takes control of Rancho Cordova's Cesca Therapeutics Aug 26 2016
CESCA THERAPEUTICS INC. Files SEC form 8-K, Termination of a Material Definitive Agreement,... Aug 25 2016
CESCA THERAPEUTICS ANNOUNCES CONVERSION OF $12.5 MILLION IN SENIOR SECURED DEBT TO EQUITY Aug 25 2016
Cesca Therapeutics Announces Conversion of $12.5 Million in Senior Secured Debt to Equity Aug 24 2016
Cesca Therapeutics raises $2.5 million in private placement of stock Aug 04 2016
CESCA THERAPEUTICS ANNOUNCES PRICING OF $2.5 MILLION REGISTERED DIRECT OFFERING Aug 04 2016
CESCA THERAPEUTICS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation... Aug 04 2016
Cesca Therapeutics Announces Pricing of $2.5 Million Registered Direct Offering Aug 04 2016
Here’s A Look At Two Promising CLI Companies And Their Near Term Milestones – Pluristem... Aug 03 2016
Here’s Why These Five Stocks Are Gaining Ground Today Aug 03 2016
Cesca Therapeutics Announces Promising Results From 40-Month Follow-Up of Patients Enrolled in... Aug 03 2016
Cesca Therapeutics Announces Publication of Results on Use of Its Technology for Treatment of... Aug 02 2016
Cesca Therapeutics provides update on FDA review of investigational device exemption supplement for... Aug 01 2016
CESCA THERAPEUTICS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 01 2016
Cesca Therapeutics Provides Update on FDA Review of Investigational Device Exemption Supplement for... Aug 01 2016
CESCA THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Jul 12 2016
Cesca therapeutics appoints mark bagnall to its board of directors Jun 21 2016
CESCA THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Jun 20 2016
Cesca Therapeutics Appoints Mark Bagnall to Its Board of Directors Jun 20 2016
Cesca Therapeutics to Exhibit at 14th International Cord Blood Symposium Jun 08 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)